CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 506 enrolled
Drug / intervention
ABT-493/ABT-530 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02640157
NCT02640157Phase 3Completed
CompareCT.gov

A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)

AbbVie·interventional·Posted Dec 28, 2015·Updated Jul 30, 2021

In Brief

A Phase 3 clinical trial evaluating ABT-493/ABT-530, Sofosbuvir, and 1 other intervention for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 506 participants.

Detailed Summary

The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic hepatitis C virus (HCV) infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 28, 2015
Enrollment StartDec 1, 2015
Primary CompletionOct 1, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.5 years ago

Interventions

ABT-493/ABT-530drug

Tablet; ABT-493 coformulated with ABT-530

Sofosbuvirdrug

Tablet

Daclatasvirdrug

Tablet